Cortexin is the bovine-cortex-derived polypeptide preparation manufactured by Geropharm (Russia) and used clinically in the Russian Federation and some CIS countries for neurological indications. Its distinctive positioning within the Russian/CIS multi-component neuropeptide-preparation family is a substantial paediatric neurological indication base — perinatal CNS injury, developmental delay, ADHD-adjacent indications, and cerebral-palsy-adjacent contexts — that is broader than the paediatric evidence base for Cerebrolysin or Cellex.

This paediatric emphasis reflects the compound's original clinical development context and the Russian paediatric-neurological community's continuing use of the preparation as an adjunct in these indications.

The paediatric evidence base uses a range of standardised paediatric neurological assessments including motor-function scores, cognitive-development scales, speech-and-language function measures, and behavioural-endpoint measures appropriate to the specific indication.

Trials run on 10-day intramuscular Cortexin courses (dose ranging with age and weight), typically repeated after intervals for chronic indications. The intervention is adjunct to standard paediatric neurological care — physiotherapy, occupational therapy, speech-and-language therapy, and the appropriate pharmacological care where indicated. The trials answer whether adjunct Cortexin produces measurable additional functional improvement.

The consistent finding across the Russian paediatric evidence base is functional improvement in the Cortexin arm relative to standard-care controls. Effect magnitudes vary by indication and age-group, with the strongest signals typically reported in the earlier-intervention perinatal-injury contexts and developmental-delay indications.

In perinatal CNS injury cohorts, motor-function endpoints and cognitive-development endpoints both improve. In developmental-delay cohorts, speech-and-language function shows the strongest signal, with cognitive-endpoint improvements following. In ADHD-adjacent indications, behavioural-endpoint improvements are reported alongside cognitive-function improvements.

Well-tolerated safety profile across the paediatric evidence base with only occasional mild reactions, providing a favourable adjunct-therapy risk-benefit picture in the Russian clinical framework.

The same methodological caveats that apply to the broader Russian neurological-peptide evidence base apply here — predominantly open-label or single-blind designs rather than double-blind placebo-controlled, concentrated in Russian centres with shared methodology, uncertain publication bias, and no independent Western meta-analytic scrutiny.

The paediatric emphasis adds distinctive additional considerations: paediatric trial design is inherently more difficult than adult trial design, endpoint measures are more subjective, and blinding of families and rating clinicians is harder to maintain than in adult indications. These considerations tend to inflate observed effect sizes relative to true effect sizes.

The Russian paediatric Cortexin evidence base is substantial and provides real support for the compound's use as an adjunct in the specific paediatric indications it targets, within the Russian clinical framework. Extrapolation to Western clinical contexts is not directly supported by the evidence — Western paediatric neurology practice does not use Cortexin, and there is no MHRA or EMA licensed use in these indications.

For research purposes the paediatric evidence base provides a credible motivation for translational work on Cortexin's mechanism-of-action in developing CNS and injury-recovery contexts. For clinical purposes — outside Russia and CIS — Cortexin remains a research chemical.